Browsing by Author "Esen-Danaci, A"
Now showing 1 - 20 of 28
Results Per Page
Sort Options
Item Does cancer diagnosis cause suicide? How can risk perception and reduction be done?Aydin, O; Deveci, A; Esen-Danaci, ACancer is a disease that requires a long-term treatment, therefore, its psychological impact on patients is important for clinical oncology. Despite improvements in medicine over the years, cancer continues to be an illness that inspires panic and anxiety among people, involves ambiguity, and evokes a death fraught with pain and suffering. Various studies show increased risk of suicide in people diagnosed with cancer. The prevalence of psychiatric disorders among inpatient and outpatient cancer patients is approximately 50%. Many studies have shown that unrelieved pain, major depression, loss of control, emotional distress, and loss of physical functioning are the leading factors that may cause suicidal thoughts in cancer patients. The physician should be alert to such patient characteristics, make a good risk assessment, and be able to take appropriate action especially on patients at a high risk for suicide. The patient who attempted suicide must be seen by a psychiatrist as soon as the medical intervention is completed. Because, this period is often referred to as the period when people are in need for help like they have never been before. Psychotherapeutic modalities should not be time consuming; they should take into account the general condition of the patients, and involve their family members and the treatment team as necessary. It is both the psychiatrists' and the patient's primary physician's responsibility to find out and resolve the psychiatric conditions associated with the suicide. Solution-focused interventions that comply with this approach will contribute greatly to improving the quality of life of patients.Item The evaluation of the effect of mindfulness and metacognition on anxiety symptoms: A case-control studyAydin, O; Obuca, F; ÇCakiroglu, E; ÜUnal-Aydin, P; Esen-Danaci, AItem Serum brain-derived neurotrophic factor levels in conversion disorder: Comparative study with depressionDeveci, A; Aydemir, O; Taskin, O; Taneli, F; Esen-Danaci, AThe aim of the present study was to compare serum brain-derived neurotrophic factor (BDNF) levels of patients with major depressive disorder (MDD) and conversion disorder (CD). Serum BDNF levels were measured in the following three groups: 15 CD patients without any comorbid diagnosis of psychiatric disorder, 24 patients with MDD, and 26 healthy subjects without any psychiatric diagnosis or psychiatric treatment. The serum BDNF level of the healthy control group (31.4 +/- 8.8 ng/mL) was statistically higher than the level of the MDD group (21.2 +/- 11.3 ng/mL) and the CD group (24.3 +/- 9.0 ng/mL; P = 0.008). This suggests that BDNF level may play a similar role in the pathophysiology of MDD and CD.Item Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Schizophrenic Patients with Depressive Sypmptoms: A Preliminary StudyEsen-Danaci, A; Aydemir, Ö; Deveci, A; Taneli, F; Taskin, OObjectives: Evidence from clinical, pharmacological and animal studies, have led to neurodevelopment, neurodegeneration, and dopamine hypotheses, and to the investigation of BDNF as a potential candidate molecule in the pathophysiology of schizophrenia, The aim of this study is to investigate the BNDF levels of schizophrenic patients with depression and compare them with major depression patients and controls in order to understand the nature of depressive symptoms seen in schizophrenia. Methods: The BDNF levels of eight schizophrenic patients with depressive symptomatology (SD) were compared with two control groups. The first group consisted of major depressed patients (MDD) (n=24) and the second was the healthy control group (n=26). Results: SD group had BDNF levels similar to control group and MDD group had significantly lower levels than the other two groups. Conclusion: This difference of BDNF levels between schizophrenia with depression group and major depression group supports the hypothesis of distinct etiologies.Item Serum BDNF levels in suicide attempters related to psychosocial stressors: A comparative study with depressionDeveci, A; Aydemir, O; Taskin, O; Taneli, F; Esen-Danaci, AAlthough many studies have examined the neurobiological aspects of suicide, the molecular mechanisms and pathophysiologic mechanisms associated with suicide remain unclear. In this study, it is aimed to investigate whether there is a difference in serum brain-derived neurotrophic factor ( BDNF) levels among suicide attempters without a major psychiatric disorder, compared to major depressive disorder patients and healthy subjects. It was undertaken with the hypothesis that suicide per se lowers serum BDNF levels, since it is a source of stress. The study was carried out in Celal Bayar University Hospital, Manisa, Turkey. Ten suicide attempters, 24 patients with major depressive disorder and 26 subjects without any psychiatric diagnosis and any psychiatric treatment were included in the study. All subjects were asked to give their written consent. Blood samples were collected at the baseline. Serum BDNF was kept at - 70 degrees C before testing, and assayed with an ELISA kit ( Promega; Madison, Wisc., USA) after dilution with the block and sample solution provided with the kit. The data were subjected to the Kruskal-Wallis test for nonparametric analysis of variance. Mean serum BDNF levels were significantly lower in the suicide group (21.2 +/- 12.4 ng/ml) and the major depressive disorder group (21.2 +/- 11.3 ng/ml) than the control group (31.4 +/- 8.8 ng/ml; p = 0.004). These results suggest that BDNF may play an important role in the neurobiology of suicidal behavior. BDNF levels may be a biological marker for suicidal behavior. To investigate the role of BDNF in suicide, further studies with a wider sample size and a variety of psychiatric diagnoses accompanying suicide attempt are needed. Copyright (c) 2007 S. Karger AG, Basel.Item Serum brain-derived neurotrophic factor level in dysthymia: A comparative study with major depressive disorderAydemir, O; Deveci, A; Taskin, EO; Taneli, F; Esen-Danaci, AItem The validation of Turkish version of personal and social performance scale (PSP)Aydemir, Ö; Üçok, A; Esen-Danaci, A; Canpolat, T; Karadayi, G; Emiroglu, B; Sariöz, FObjective: Functioning in severe mental disorders is very important and brief functioning rating instruments are needed. Even though patients with severe psychiatric disorders achieve symptomatic recovery, most of them cannot return to their initial level of social functioning. Personal and Social Performance Scale (PSP) is one of the instruments which can be used in severe mental disorders such as schizophrenia and takes a short time to complete. Methods: The study was performed in departments of psychiatry of two university hospitals. In- or out-patients diagnosed with schizophrenia or bipolar disorders were included in the study. The exclusion criteria were comorbidity of other psychiatric disorders including substance use disorders or of physical diseases. For concurrent validity, beside PSP, Clinical Global Impression (CGI), Global Assessment of Functioning (GAF) of DSM-IV, Quality of Life and Satisfaction Questionnaire (QLS-Q), and Positive and Negative Syndrome Scale (PANSS) were used. For discriminant validity, the mean scores of PSP in patients with and without symptomatic remission were compared. Results: The study was carried out with a total of 135 patients, 105 (77.8%) patients diagnosed with schizophrenia and 30 (22.2%) patients diagnosed with bipolar disorder. The mean age of the patients was 34.1 +/- 10.7 and 75 (55.6%) of them were male. The duration of illness was 10.4 +/- 7.5 years. The mean score of PSP was found to be 60.0 +/- 17.1. In the reliability analysis, the Cronbach alpha coefficient was calculated to be 0.8327, and item-total score correlations were found to be between 0.4920-0.7462. Intraclass correlation coefficient was calculated to be 0.8324. The inter-rater reliability of PSP performed on 30 schizophrenic patients was found to be 0.973 (p<0.0001). In the validity analyses, the total score of PSP was significantly correlated with the total score of Clinical Global Impression (CGI) (r=-0.854, p<0.0001), Global Assessment of Functioning (GAF) (r=0.748, p<0.0001), Quality of Life and Satisfaction Questionnaire (QLS-Q) (r=0.734, p<0.0001), and Positive and Negative Syndrome Scale (PANSS) (r=-0.664, p<0.0001). There was a significant difference between the patients with and without symptomatic remission (54.8 +/- 14.8 vs. 72.6 +/- 9.8, t=7.434, p<0.0001). Conclusion: The Turkish version of PSP was found to be reliable and valid in severe mental disorders and was sensitive to change. It can be used both in clinical trials and routine clinical practice.Item The effect of mindfulness and metacognition on anxiety symptoms: a case-control studyAydin, O; Obuca, F; Cakiroglu, E; Ünal-Aydin, P; Esen-Danaci, ABackground Anxiety disorders (ADs) are associated with numerous psychiatric disorders; despite the efforts in psychotherapy models targeting their etiology, novel treatment strategies are still developing. We aimed to assess whether mindfulness and metacognition differ between patients with ADs and healthy controls (HCs) and whether the symptom severity of ADs is related to mindfulness and metacognition among patients. Two-hundred participants were enrolled in this study. Structured clinical interview, sociodemographic form, Five Facet Mindfulness Questionnaire-Short Form, Metacognition Questionnaire-30, and Hamilton Anxiety Rating Scale were administered. Multivariate analysis of covariance was conducted to compare the groups in terms of mindfulness and metacognition. Correlation and multiple linear regression analyses were performed to measure the association between the variables. Results The main finding indicates that positive beliefs about worry are associated with reduced symptom severity of ADs. Furthermore, HCs have more positive beliefs about worry and nonjudging of inner experience compared to patients with ADs, who utilize negative beliefs about uncontrollability and danger and need to control thoughts to a greater extent. Conclusions This study demonstrates that dysfunctional metacognitive beliefs may influence the anxiety severity of adult patients. We suggest that focusing on reducing maladaptive metacognitions may be supportive of AD improvement.Item The Effects of Psychosocial Skills Training on Symptomatology, Insight, Quality of Life, and Suicide Probability in SchizophreniaDeveci, A; Esen-Danaci, A; Yurtsever, F; Deniz, F; Gürlek-Yüksel, EObjective: The aim of this study was to determine the effect of psychosocial skills training (PST) on symptomatology, insight, quality of life, and suicide probability in patients with schizophrenia. Method: The sample consisted of 22 schizophrenic outpatients diagnosed according to DSM-IV diagnostic criteria. Three PST groups were formed and each group's training lasted approximately 6 months. Nineteen (86%) patients completed the study. The Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, Calgary Depression Rating Scale for Schizophrenia, Schedule for Assessing the Three Components of Insight, Quality of Life Scale for Patients with Schizophrenia, and Suicide Probability Scale were administered to the patients before and after PST. Results: At the end of the study mean score for the Scale for the Assessment of Positive Symptoms score (baseline 8.5 +/- +/- 9.9, post-PST 3.4 +/- +/- 6.0, P = 0.004), Scale for the Assessment of Negative Symptoms (baseline 33.7 +/- 19.3, post-PST 22.1 +/- +/- 15.7, P = 0.001), Calgary Depression Rating Scale for Schizophrenia (baseline 4.2 +/- +/- 4.1, post-PST 0.7 +/- +/- 1.0, P = 0.001), Schedule for Assessing the Three Components of Insight (baseline 11.1 +/- +/- 3.4, post-PST 16.2 +/- +/- 1.1, P < 0.0001), and Quality of Life Scale for Patients with Schizophrenia (baseline 53.5 +/- +/- 20.0, post-PST 79.6 +/- +/- 20.8, P < 0.0001) changed significantly, whereas the change in mean score for the Suicide Probability Scale (baseline 75.1 +/- +/- 11.7, post-PST 71.3 +/- +/- 8.0, P = 0.06) did not reach statistical significance. Conclusion: This study demonstrated the effects of PST on the symptoms and functioning of patients with schizophrenia. It con be concluded that using PST for the treatment of schizophrenia, as an adjuvant to pharmacotherapy, could produce significant positive results.Item The Effect of Theory of Mind Capacities of Mothers of Patients With Schizophrenia on the Severity of the DiseasesBalikçi, K; Aydin, O; Tas, C; Esen-Danaci, AObjective: Studies conducted with patients with schizophrenia and first-degree relatives show that, the pathology in theory of mind may be related to the risk of psychosis. The theory of mind capacities of the mothers may be effective in the prognosis of schizophrenia. The purpose of this study is to examine the effects of theory of mind capacities of patient mothers on the severity of the disease. Method: The study was conducted with 34 schizophrenic patients and their mothers, and 31 healthy mothers. Sociodemographic data was captures for all groups. In addition, PANSS was collected from patients and Reading Mind From Eyes Test was collected from the each patient mother. Results: There was no statistically significant difference between the age and education levels of the groups. The mothers of patients with schizophrenia performed significantly worse in the Reading Mind From Eyes Test than the control group. There was an inverse correlation between theory of mind capacity and the medication dose, PANNS general condition and PANNS total score. Discussion: The significant difference between the groups suggests that the impairment in the function of the theory of mind can be regarded as an endo-phenotype for schizophrenia. The low theory of mind capacities of the mothers of schizophrenia patients can cause the mothers to misunderstand the feelings of their patient which could lead to increase in disease severity and drugsItem Serum brain-derived neurotrophic factor level in dysthymiaAydemir, Ö; Deveci, A; Taskin, OE; Taneli, F; Esen-Danaci, AIn this present work, it is aimed to demonstrate BDNF serum concentrations in patients with dysthymia and to compare them with BDNF serum concentrations in patients with major depressive disorder and healthy subjects. The study was carried out in Celal Bayar University Hospital, Manisa, Turkey. Seventeen patients with dysthymia, 24 patients with major depressive disorder and 26 subjects without any psychiatric diagnosis and any psychiatric treatment were included in the study. The severity of depression was assessed with 17-item HAM-D. All subjects were asked to give their written consent. Blood samples were collected at baseline. Serum BDNF was kept at -70 degrees C before testing, and assayed with an ELISA Kit (Promega; Madison, WI, USA), after dilution with the Block and Sample solution provided with the kit. The data were subjected to the analysis of variance. The BDNF serum concentrations of the dysthymia group (mean=28.9 +/- 9.2 ng/ml) were significantly higher than that of the major depressive disorder group (21.2 +/- 11.3 ng/ml) (p=0.002), and it was not different from the level of the control group (31.4 +/- 8.8 ng/ml). BDNF serum concentrations and HAM-D score did not have any significant correlation in the dysthymia and major depression groups (r=-0.276, p=0.086). The low level of BDNF in patients with dysthymic disorder seems to point out that BDNF changes in mood disorders are state-dependent and vary according to the severity of depressive episodes. (c) 2007 Elsevier Inc. All rights reserved.Item Does the family history of diabetes has an effect on the glucose metabolism of the patients recieving atypical antipsychotics?Yurtsever, F; Esen-Danaci, A; Taneli, F; Gunay, O; Veznedaroglu, BItem The effect of emotion recognition and mindfulness on depression symptoms: A case-control studyAydin, O; Tvrtkovic, S; Cakiroglu, E; Ünal-Aydin, P; Esen-Danaci, AAbnormalities in emotion recognition (ER) are frequently reported in depression, with lower recognition accuracy in patients with major depressive disorder (MDD) when compared to healthy individuals. Mindfulness was found to directly impact the severity of depressive symptoms, by recognizing negative cognitions and dysfunctional reactions. The aims of this study were to compare ER and mindfulness levels between MDD patients and healthy controls (HCs), as well as to examine whether ER and mindfulness are related to symptom severity in MDD patients. Sixty-eight patients with MDD and 93 HCs participated in the study. A sociodemographic form, reading the mind in the eyes test (RMET), five facet mindfulness questionnaire-short form (FFMQ-S) and the Montgomery-Asberg depression scale (MADRS) were administered. Group comparison in ER and mindfulness was performed using the multivariate analysis of covariance (MANCOVA). Bivariate correlations and hierarchical linear regression analyses were performed to assess the associations between depression severity, ER and mindfulness in the patient group. Higher level of mindfulness was found in HCs relative to MDD group, however, no ER difference was present between the groups. A positive association between depression severity and the non-reactivity facet of mindfulness was found. On the other hand, ER was not significantly associated with symptom severity among individuals with MDD. Non-reactivity, unlike other dimensions of mindfulness, seems to increase with the severity of depressive symptoms among MDD patients. A particular focus on this subdimension in mindfulness techniques may yield better outcomes in alleviation of depressive symptoms.Item Effects of clozapine, olanzapine and risperidone on glucose and lipid metabolismsYurtsever, F; Esen-Danaci, A; Taneli, F; Gunay, O; Veznedaroglu, BItem Are pain syndromes equivalents of depression? A comparative study on the level of brain-derived neurotrophic factorAydemir, O; Deveci, A; Taskin, EO; Taneli, F; Selcuki, D; Cerrahoglu, L; Esen-Danaci, AItem The effect of emotion recognition and mindfulness on depression symptoms: A case-control studyAydin, O; Tvrtkovic, S; Çakiroglu, E; Ünal-Aydin, P; Esen-Danaci, AItem Venlafaxine treatment of depression in schizophrenia: An eight-case reportAydemir, O; Esen-Danaci, AItem Serum BDNF levels in conversion disorder: A comparative study with depressionDeveci, A; Aydemir, O; Taskin, EO; Taneli, F; Esen-Danaci, AItem OXIDATIVE STRESS IS RELATED TO NEUROCOGNITION BUT NOT SOCIAL COGNITION IN PATIENTS WITH SCHIZOPHRENIAEsen-Danaci, A; Gonzalez-Liencres, C; Tas, C; Brown, EC; Erdin, S; Onur, E; Cubukcoglu, Z; Aydemir, O; Esen-Danaci, A; Brüne, MItem A closer look at the relationship between the subdomains of social functioning, social cognition and symptomatology in clinically stable patients with schizophreniaBrown, EC; Tas, C; Can, H; Esen-Danaci, A; Brüne, MImpairments in social functioning commonly seen in schizophrenia are thought to be mediated by deficits in the domains of social cognition. Some previous research has explored how social cognitive skills and psychotic symptoms are associated with social functioning, however these associations are still under debate. The main aim of this study was to investigate the relationship between different domains of social cognition and psychotic symptomatology, and also to look at the relationships with individual subdomains of social functioning within a clinically stable schizophrenia population. 45 outpatients were recruited and symptoms were assessed with the PANSS, and measures of emotion processing, affective and cognitive theory of mind (ToM), mental state reasoning attributional biases, and social functioning were taken. A correlational analysis was performed with the data. Following this, a regression analysis was used to reveal which domains of social cognition best predicted psychotic symptoms. In this stable group of patients, our results support the suggestion of a likely distinction between affective and cognitive components of ToM. The study also demonstrated that ToM and mental state reasoning were the best predictors of psychotic symptoms. Here we reveal that cognitive ToM had the most widespread relationship with social functioning, across multiple subdomains, while only some specific subdomains of social functioning correlated with other domains of social cognition and symptomatology. Further to this, positive symptoms were associated with much fewer subdomains of social functioning than negative and general symptoms. These findings imply that different aspects of social functioning may be served by different domains of social cognition and symptomatology. (C) 2014 Elsevier Inc. All rights reserved.